title: Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men.
abstract: The enzyme paraoxonase (PON) can eliminate lipid peroxides and is believed to protect against low-density lipoprotein oxidation. A common polymorphism in the PON gene (PON1) causes an amino acid substitution of methionine (M) for leucine (L) at position 55 in the protein, which changes the activity of PON and can affect the risk of atherosclerosis. Because smoking is associated with increased lipid peroxidation, we studied the relationship between PON M/L55 polymorphism and the carotid artery intima-media thickness (IMT) in smokers or previous smokers (n = 112) and nonsmokers (n = 87). IMT was measured at 3 standardized segments by B-mode ultrasonography, and the overall mean IMT value of 199 randomly selected men (mean age 54.2 +/- 3.0 years) was calculated. Subjects with IMT > 1.7 mm in at least 1 standard site were considered to have carotid artery atherosclerotic disease (CAAD). For analysis, L55 homozygotes were compared with the M55 allele carriers. Nonsmoking L55 homozygotes had an 8.9% (95% confidence interval [CI], 1.6 to 16.8) higher overall mean IMT than M55 allele carriers. In smokers, however, the M55 allele carriers tended to have higher overall mean IMT values than L55 homozygotes. There was also a statistically significant interaction between M/L55 genotype and smoking status on CAAD (P =.009) by logistic regression analysis. Among nonsmokers, the L55 homozygotes had an odds ratio of 4.22 (95% CI, 1.06 to 16.8) for CAAD compared with nonsmoking M55 allele carriers. Contrary to nonsmokers, the smoking M55 allele carriers had an odds ratio of 2.22 (95% CI, 0.82 to 6.01) for CAAD when the L55/L55 genotype of smokers was a reference group. These data suggest that in nonsmoking men, a PON L55/L55 genotype may represent a genetic risk factor for CAAD. The reverse effect in smokers implies that the ability of PON to protect against CAAD is influenced by cigarette smoking. The efficiency of this inhibition probably depends on the PON M/L55 genotype.
authors.affiliation: Centre for Laboratory Medicine, Department of Clinical Chemistry, Tampere University Hospital, Tampere, Finland.
authors.forename: R
authors.initials: R
authors.lastname: Malin
authors.forename: A
authors.initials: A
authors.lastname: Loimaala
authors.forename: A
authors.initials: A
authors.lastname: Nenonen
authors.forename: M
authors.initials: M
authors.lastname: Mercuri
authors.forename: I
authors.initials: I
authors.lastname: Vuori
authors.forename: M
authors.initials: M
authors.lastname: Pasanen
authors.forename: P
authors.initials: P
authors.lastname: Oja
authors.forename: G
authors.initials: G
authors.lastname: Bond
authors.forename: T
authors.initials: T
authors.lastname: Koivula
authors.forename: T
authors.initials: T
authors.lastname: Lehtimäki
mesh_terms: D000483:Alleles; D019943:Amino Acid Substitution / Q000235:genetics; D043303:Aryldialkylphosphatase; D002339:Carotid Arteries / Q000000981:diagnostic imaging; D002340:Carotid Artery Diseases / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000235:genetics*; D004950:Esterases / Q000235:genetics*; D005387:Finland / Q000453:epidemiology; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D015227:Lipid Peroxidation / Q000235:genetics; D008075:Lipoproteins, HDL; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects* / Q000453:epidemiology; D014463:Ultrasonography
chemical_list: D008075:Lipoproteins, HDL; D004950:Esterases; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human